2 institutional holders with $534.6K total value (23,123 shares) as of 2025-Q4. Top holders: MORGAN, WELLS. Net buying activity: 1 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	MORGAN STANLEY	22,923	$530.0K	99.1%	DOUBLED +864.0%
2	WELLS FARGO & COMPANY/MN	200	$4.6K	0.9%	—

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
MORGAN STANLEY	DOUBLED	2,378	22,923	+864.0%	$530.0K	2025-Q4
MORGAN STANLEY	TRIM	5,300	2,378	-55.1%	$44.9K	2025-Q3
UBS Group AG	TRIM	4,418	2,161	-51.1%	$40.8K	2025-Q3
UBS Group AG	ADD	3,000	4,418	+47.3%	$20.9K	2025-Q2
MORGAN STANLEY	DOUBLED	2	5,102	+255000.0%	$14.6K	2024-Q4

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

5 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.

BULLISH 6-K 7/10

Nanobiotix announced Part 1 data from the CONVERGE Phase 2 trial of JNJ-1900 (NBTXR3) in stage 3 ino

May 18, 2026

BULLISH 6-K 6/10

Nanobiotix announced preclinical data showing that its Nanoprimer technology improves systemic bioav

Apr 20, 2026

NEUTRAL 6-K 2/10

Nanobiotix filed a routine 6-K disclosing its voting rights and share capital as of March 31, 2026,

Apr 7, 2026

BULLISH 6-K 7/10

Nanobiotix announced first data from a Johnson & Johnson-sponsored Phase 2 trial of JNJ-1900 (NBTXR3

Mar 30, 2026

NEUTRAL 6-K 3/10

Nanobiotix S.A. announced it will release its fourth quarter and full year 2025 financial results on

Mar 26, 2026

BEARISH 6/10

Nanobiotix priced a global follow-on offering of 2,184,662 ordinary shares (including ADSs) and 345,

May 21, 2026

BEARISH 6/10

Nanobiotix priced a global follow-on offering raising ~$98.6M gross ($85M equivalent) via 2,184,662

May 21, 2026

BEARISH 6/10

Nanobiotix has temporarily halted trading on Euronext Paris to finalize allocations and announce pri

May 21, 2026

BEARISH 5/10

Nanobiotix launched a ~€75M (~$87M) global follow-on offering of ADSs and ordinary shares, plus pre-

May 20, 2026

BULLISH 7/10

Nanobiotix announced Part 1 data from the Johnson & Johnson-sponsored Phase 2 CONVERGE study of NBTX

May 17, 2026

NEUTRAL 5/10

Nanobiotix announced FDA acceptance of a protocol amendment to its pivotal NANORAY-312 study for JNJ

May 4, 2026

NEUTRAL 3/10

Nanobiotix S.A. announced it will release its fourth quarter and full-year 2025 financial results on

Mar 26, 2026

NEUTRAL 3/10

Nanobiotix (NBTX) issued a press release denying recent media speculation about a potential takeover

Mar 25, 2026

Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 4 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$34.17 mean target -13.7% upside Sell (1.57)

$25.71 Low $40.69 High

Metric	Value
Current Price	$39.57
Target Low	$25.71
Target Mean	$34.17
Target Median	$36.04
Target High	$40.69
# Analysts	6
Recommendation	Sell (1.57)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Next Q	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Current FY 2026-12-31	$0.07	$-0.60	$0.68	114.5%	+164.0%	0↑ 1↓	$0.0B	30.9%	4
Next FY 2027-12-31	$0.13	$-0.55	$1.38	72.5%	+101.6%	1↑ 0↓	$0.1B	30.4%	4

2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
May 1, 2026	UBS	MAINTAIN	Neutral	Neutral
Apr 2, 2026	Guggenheim	MAINTAIN	Buy	Buy
Feb 6, 2026	Guggenheim	MAINTAIN	Buy	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
May 1, 2026	4	7	1	92%
Apr 1, 2026	4	7	1	92%
Mar 1, 2026	4	7	1	92%
Feb 1, 2026	4	7	1	92%
Jan 1, 2026	5	6	1	92%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 21, 2026

offering

Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering

PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobio

May 21, 2026

offering

Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering

PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobio

May 21, 2026

other

Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris

PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix</str

May 21, 2026

offering

Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris

PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix</str

May 20, 2026

offering

Nanobiotix Announces Launch of Global Follow-On Offering

PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix</str

May 20, 2026

offering

Nanobiotix Announces Launch of Global Follow-On Offering

PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix</str

May 17, 2026

announcement

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting <pre>Data presented by Johnson &

May 4, 2026

fda

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

PARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=9ESaxEraoujroKN

Apr 20, 2026

routine

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology

Data presented at the 2026 Annual Meeting of the American Association for Cancer Research

Apr 7, 2026

other

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (A

Mar 31, 2026

earnings

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

Conference call and webcast scheduled for April 1, 2026, at 8:00 A.M. EDT / 2:00 P.M. CEST

Mar 30, 2026

other

NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference

Mar 26, 2026

earnings

NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST <pre>Conference call and webcast scheduled for Wed

Mar 25, 2026

m_and_a

NANOBIOTIX Statement Regarding Recent Media Speculation

PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=U8johXClESc8OI

Mar 12, 2026

activist

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French